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Abstract
In Drosophila melanogaster the male specific lethal (MSL) complex is required for upregulation of expression of most X-
linked genes in males, thereby achieving X chromosome dosage compensation. The MSL complex is highly enriched across
most active X-linked genes with a bias towards the 39 end. Previous studies have shown that gene transcription facilitates
MSL complex binding but the type of promoter did not appear to be important. We have made the surprising observation
that genes driven by the glass multiple reporter (GMR) enhancer-promoter are not dosage compensated at X-linked sites.
The GMR promoter is active in all cells in, and posterior to, the morphogenetic furrow of the developing eye disc. Using
phiC31 integrase-mediated targeted integration, we measured expression of lacZ reporter genes driven by either the GMR
or armadillo (arm) promoters at each of three X-linked sites. At all sites, the arm-lacZ reporter gene was dosage
compensated but GMR-lacZ was not. We have investigated why GMR-driven genes are not dosage compensated. Earlier or
constitutive expression of GMR-lacZ did not affect the level of compensation. Neither did proximity to a strong MSL binding
site. However, replacement of the hsp70 minimal promoter with a minimal promoter from the X-linked 6-Phosphogluconate
dehydrogenase gene did restore partial dosage compensation. Similarly, insertion of binding sites for the GAGA and DREF
factors upstream of the GMR promoter led to significantly higher lacZ expression in males than females. GAGA and DREF
have been implicated to play a role in dosage compensation. We conclude that the gene promoter can affect MSL complex-
mediated upregulation and dosage compensation. Further, it appears that the nature of the basal promoter and the
presence of binding sites for specific factors influence the ability of a gene promoter to respond to the MSL complex.
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Introduction
The Drosophila eye is well suited to genetic investigations, as it is
a dispensable tissue with mutant phenotypes that are relatively
easy to identify [1]. Glass is a Zinc-finger transcription factor
involved in photoreceptor development, present in the eyes, ocelli,
small areas of the brain, and the embryonic Bolwig organ [2,3].
The glass multiple reporter (GMR) is a pentamer of a 27 bp Glass
response element from the Rh1 (ninaE) promoter, upstream of a
minimal promoter from the hsp70 gene [4]. The GMR enhancer-
promoter drives expression in all cells in, and posterior to, the
morphogenetic furrow in the developing eye imaginal disc [5,6].
Expression of the pro-apoptotic hid gene from GMR kills eye cells
proportional to the GMR-hid expression level; a smaller eye with
higher levels [7]. This reporter system facilitated a mutational
screen for apoptosis-related factors, by identifying modifiers of
GMR-hid-derived eye size [8]. We sought to use the variable eye
size of GMR-hid to screen for modifiers of Drosophila dosage
compensation, but observed that GMR-hid did not report on
dosage compensation. We have thus investigated why GMR-hid
failed to respond, and report that the minimal hsp70 promoter
appears refractory to the compensation machinery.
Drosophila males (XY) lack a dose of X-linked genes in
comparison to (XX) females, but compensate for this by doubling
transcription from the single X chromosome [9,10,11]. Dosage
compensation requires the action of the RNA-containing Male-
Specific Lethal (MSL) complex, which cannot form in females as
translation of msl2 RNA is repressed by the female-specific SXL
protein [12]. The MSL complex specifically binds to many sites on
the male X chromosome and modifies the chromatin, most
notably by acetylating histone H4 at lysine16 (H4K16) [13]. The
enrichment for H4K16ac across active genes could lead to a less
compact chromatin structure as incorporation of H4K16ac into
nucleosomal arrays abolished a salt-dependent compaction into
30 nm-like fibres in an in vitro assay [14]. However, it has been
reported that H4K16ac is more strongly associated with DNA
replication timing than transcription in Drosophila cells [15]. Thus
the exact mechanism of transcription enhancement by the MSL
complex is unknown. It has been suggested that the MSL complex
may enhance transcription elongation as the MSL complex is
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[16,17,18,19]. Indeed, using a global run-on sequencing (GRO-
seq) approach, Kuroda and colleagues concluded that the MSL
complex enhances transcription by facilitating the progression of
RNA polymerase II along X-linked gene [20].
The dosage compensation machinery can also affect genes that
are not endogenous to the X chromosome. Translocations of
genomic fragments between the X chromosome and autosomes
exhibit ‘‘spreading’’ of the MSL complex from the X-linked
sequences into the adjacent autosomal regions [21]. This ability of
the MSL complex to bind autosomal genes is likely the reason why
autosomal genes translocated to the X chromosome usually gain
increased transcription in males [22,23,24]. Short sequences with
strong affinity for MSL complex can recruit the complex to
autosomes, and increase the transcription of neighbouring genes
[25,26,27,28]. These MSL-binding High Affinity Sites (HAS) are
thought to serve as primary attractors of the MSL complex to the
X chromosome, from which it can then ‘‘spread’’ to affect the
transcription of nearby active genes [29]. Indeed, chromosome-
wide studies of MSL binding find that most MSL-bound genes are
active [17]. Thus, we expected the (active) GMR-hid to respond to
dosage compensation, but found that it was unable to fully do so.
We argue that an active gene is not sufficient for recognition by the
dosage compensation machinery, even if near a HAS, and
specifically that the hsp70 minimal promoter appears to hinder
dosage compensation.
We also report two further observations of oddities in expression
from GMR that will be of interest to those working with this
enhancer-promoter. Activity of beta-galactosidase produced by a
GMR-lacZ transgene was not linear with respect to gene dose, at
least in the environment of the female X chromosome. The
activity in females with two copies of the transgene was more than
twice the activity in single-copy females, suggesting some synergy
in homozygosity. Further, we detected some repression of
expression from GMR in the larval imaginal tissue, consistent
with that first reported for an earlier Glass-based eye reporter that
contained a longer glass response element [30]. Both these
observations have implications for dosage compensation, but in
general they also call for careful use of the GMR enhancer-
promoter.
Results
GMR-hid is a poor reporter of dosage compensation
Our understanding of the mechanism of X chromosome dosage
compensation may need to better appreciate the balance between
the MSL complex and the wider network of chromatin regulators.
Identification ofallfactorsthat playaroleindosage compensationis
nottrivial.ThefiveMSLproteins(MSL1,MSL2,MSL3,MLE,and
MOF) were identified based on mutant phenotypes of male-specific
lethality [31,32]. Loss of function mutations in genes for more
generally acting epigenetic modifiers would be expected to be
homozygous lethal for both sexes. However, some factors have been
implicated to have a role in dosage compensation based on
hypomorphic phenotypes of reduced male viability or altered male
X chromosome morphology [10]. Such factors include the DNA
supercoiling factor [33], JIL-1 histone kinase [34] and the
heterochromatin-associated protein SU(VAR)3–7 [35]. The initial
aim of this study was to search for novel dosage compensation
factors, not by screening for male-lethality, but by using the reduced
eye size of GMR-hid to screen for mutations that affected the end
product of dosage compensation: the equalization of phenotype.
We followed two strategies to adapt the GMR-hid system to
report on Drosophila dosage compensation, with the aim of then
conducting a mutagenesis screen for modifiers of dosage
compensation. To obtain a sex-specific difference in eye size, we
created P-element transgenic lines carrying GMR-hid, and screened
for those genetically linked to the X chromosome (Figure 1A).
Transgenic insertions on the X chromosome usually acquire a
degree of compensation [22,23,24], meaning that males with one
transgene copy express more than single-copy females, and
perhaps as much as two-copy females. In all cases, flies
homozygous for the GMR-hid transgene had ablated eyes
(Figure 1A) representing high levels of transgene expression, but
little information as to what level of expression. All lines
homozygous for any GMR-hid transgene were weak, presumably
due to leaky expression of hid from the basal hsp70 TATA, or
expression in other neuronal tissues. Flies heterozygous for all
autosomal GMR-hid insertions had similar eye sizes in each sex
(Figure 1B). Surprisingly, lines with X-linked insertions of GMR-hid
also showed very little difference in eye size between the sexes. In
most cases, (hemizygous) male eyes were only slightly smaller than
heterozygous female eyes; both sexes having a small range of sizes
that just overlapped. The line with greatest difference and least
overlap between the sexes (line C60) was selected for further
analysis.
To validate the usefulness of the line in a mutagenesis screen, we
crossed line C60 to flies deficient in msl1, msl2, and mle. Flies
heterozygous for both GMR-hid and each msl deficiency (GMR-hid/
+; msl1 msl2 mle/+) had similar sized eyes to those without the msl
deficiency (Figure S1), indicating an inability to report on
mutations in known MSL components. As an alternative genetic
test to determine if GMR-hid could respond to the MSL complex,
we crossed line C60 to a line that constitutively expresses MSL2.
Females with hsp83-msl2 can assemble MSL complex, erroneously
up-regulate X-linked gene expression, and thus have poor viability
[36]. However, GMR-hid/+; hsp83-msl2/+ females were identical
to females that lacked the hsp83-msl2 transgene (Figure S1),
indicating that the sex-specific eye size may not have reflected
action by the MSL complex. The strategy seemed unsuitable for
the proposed mutagenic screen.
In a complementary approach, we sought to directly attract
MSL complex to autosomal insertions of GMR-hid by coupling the
transgene to the strongest known MSL binding sites. The MSL
complex binds with high affinity to a DNase I hyper-sensitive site
(DHS) in the X-linked roX1 gene [26]. The long roX1 noncoding
RNA is a component of the MSL complex. roX1 expression is
tightly regulated through a combination of constitutive repression
and male-specific hyper-activation by the MSL complex that
antagonises the repression [37]. Ectopic autosomal insertions of
the roX1 DHS attract significant amounts of MSL complex to the
insertion site, clearly visible by immuno-fluorescent labelling of
polytene chromosomes, and a nine-copy multimer of the DHS is
particularly effective [26]. The roX1 DHS is also capable of
mediating increased activity of a coupled lacZ reporter gene at
autosomal insertions [25].
We created roX1 DHS-GMR-hid, and (roX1 DHS)9-GMR-hid,
and observed the eye phenotype in flies carrying autosomal
insertions of each (Figure 1C,E). Lines carrying single insertions of
roX1-DHS-GMR-hid had eyes of equal size in each sex. Those with
the nine-copy multimer of the binding site displayed a range of eye
sizes, mostly larger than for roX1 DHS-GMR-hid, with male eyes in
most cases slightly smaller than female eyes. Thus, eye size did not
respond well to any MSL complex recruited by the roX1 DHS.
The MSL complex binds the X chromosome most strongly at
hundreds of MSL Recognition Elements (MREs), GA-rich motifs
that are found predominantly in intergenic or intronic sequences
[38,39]. The MRE at cytological position 18D11 has strong
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ectopic autosomal insertion site, especially when multimerized
[40]. We placed both the MRE from 18D11 and the tetramer of
the site in the 39 UTR of GMR-hid, to mimic the normally high
concentrations of MSLs towards the 39 end of a transcript.
However, flies transgenic for either construct still displayed eyes of
similar size in males and females (Figure 1 D, F). It appeared that
directly attracting MSL complex to GMR-hid did not improve the
ability of the reporter to respond to dosage compensation.
The failure of GMR-hid to report might have been due to an
inability to report two-fold transcriptional changes as an altered
eye size. However, we observed a wide range of possible eye sizes
(that likely reflected position effects on transgene expression), and
the system has displayed great sensitivity previously [8]. Further,
the ablated eye phenotype of two copy females showed that the
system was dose-responsive. Instead, we theorized that GMR-hid
was not amenable to dosage compensation. An alternative,
although unlikely explanation, was the MSL complex was not
recruited to the transgenes containing a roX or 18D11 high affinity
site. Yet, in (roX1 DHS)9-GMR-hid lines (Figure 1 E) female eye
color was generally lighter than males, and in some cases
indistinguishable from white. Additionally, there was variegation
in pigmentation in some lines (e.g. C20, C21). This is consistent
with general repression of the mini-white transformation marker
gene, responsible for the red pigment, with male-specific relief by
the MSL complex, as previously observed at some autosomal
insertions of mini-white when coupled to a roX1 transgene [41].
This suggests the MSL complex was recruited to the multimer of
the roX1 DHS, sufficient to relieve repression of mini-white, but
with little effect on GMR-hid expression.
The promoter can affect compensation
To more quantifiably measure compensation of a GMR-driven
transgene, we used the enhancer-promoter to drive the beta-
galactosidase gene lacZ, and compared beta-galactosidase activity
from several related constructs (Figure 2). To measure the degree
of up-regulation and compensation supported by GMR-mediated
expression, we compared the response of GMR-lacZ at X-linked
sites to that of lacZ driven by the constitutive promoter from the X-
linked armadillo (arm) gene. We have previously shown that X-
linked insertions of arm-lacZ generally acquire dosage compensa-
tion [24,42]. To remove position effects of integration, we used the
phiC31 recombinase system to target transgenic constructs to
defined attP landing sites [43]. We tested five X-linked landing sites
Figure 1. GMR-hid constructs were expressed similarly in both sexes. A, C–F) Drosophila eyes from transgenic lines (e.g. C32) carrying one
copy of the indicated constructs. A) Lines C70, C72 and C74 are phi-C31 mediated insertions at the attP sites 2A, 6E and 20C respectively. B) An
example eye from a female homozygous for GMR-hid construct. G) Eye from wild-type (Canton S). In all panels right eyes are shown, dorsal up,
anterior right. Bar =0.2 mm.
doi:10.1371/journal.pone.0020455.g001
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insertions at attP-3B, and found that insertions at attP-3Aa were
either male-lethal or ectopically integrated. Of the three remaining
sites, attP-2A and attP-6E were within 20 kb of MSL binding sites
noted in MSL immuno-precipitates [19], and the peri-centromeric
attP-20C was devoid of bound MSL. Flies carrying GMR-hid at
each of these locations had eyes similar to those with P-element
insertions of the transgene (Figure 1A, lines C70, C72, C74).
We targeted both arm-lacZ and GMR-lacZ to each of the three
X-linked attP sites, and measured beta-galactosidase activity
(Table 1). We compared activities in (hemizygous) males to those
in females heterozygous for the insert, as a measure of male hyper-
activity (Figure 3, top panels). Separately, we compared males to
homozygous females, to measure dosage compensation (Figure 3,
bottom panels). We took the log2 of the ratios, to enable a more
accurate comparison of ratios above and below zero. A two-fold
increase would give a log2 of 1.0, whereas equal expression would
give 0. As expected, arm-lacZ males had nearly twice the activity of
single-copy females (top panels), nearly sufficient to compensate for
deficiency against two-copy females (bottom panels), although the
response at 6E was slightly lower. However, male activity in lines
with GMR-lacZ was only slightly above single-copy female activity,
providing effectively no dosage compensation against two-copy
females. The apparent discrepancy between the two ratios (slight
hyper-activity but no dosage compensation) is explored below. As
the lacZ sequences were identical between arm-lacZ and GMR-lacZ,
these results imply that the GMR-hsp70 regulatory sequences were
responsible for poor dosage compensation.
Why did GMR-lacZ fail to compensate? Perhaps the construct
actively blocked the compensatory machinery, although no such
elements have yet been reported. Alternatively, the construct may
have lacked some feature necessary for transcription to be
compensated. We selected the landing site at 2A, which supported
strong expression and rates of transformation, and tested the effect
of a variety of modifications to GMR-lacZ on the male hyper-
activity and dosage compensation. Since the MSL complex binds
to the body of active X-linked genes with a bias towards the 39
end, we first considered replacing the 39 hsp70 sequences with
those from SV40 that were used for arm-lacZ. The GMR-lacZ-SV40
line produced much higher levels of beta-galactosidase than GMR-
lacZ, possibly because the lacZ RNA is less stable with hsp70 39
UTR sequences [45]. There was also a small increase in male
hyper-activity and dosage compensation, in comparison to GMR-
lacZ but the increase was not statistically significant. To enhance
binding of the MSL complex to the 39 end of the transgene, we
inserted of an MRE (from 18D11) in the SV40 39 UTR of GMR-
lacZ-SV40. However, we found no measureable effect on male
hyper-transcription (Table 1).
We next considered that the GMR-hsp70 enhancer-promoter
lacked elements that are present in the arm promoter and are
required to recruit/respond to the MSL complex. The arm promoter
fragment contains short runs of GA, similar to the binding sites for
the GAGA factor [46] (Figure 2). The GAGA factor has itself been
linked to dosage compensation, as it genetically interacts with msl
mutations to alter male lethality [47]. We also identified a cluster of
four DRE-like elements inthe armadillo promoter. When analysed on
a cDNA array, DRE is over-represented in fragments bound by
MSL1 immuno-precipitates, compared to those not bound (28 and
16%, respectively), and is slightly enriched on the X chromosome
[18], implying a possible role in dosage compensation. The arm
promoter does not contain an MRE. However, an MRE is found
within the gene, but this is downstream of the promoter fragment
used in arm-lacZ (A. Alekseyenko, personal communication). We
isolated a short fragment of the armadillo promoter (arm*) spanning
the cluster of DRE-like elements and five GAGA-like elements, and
tested it upstream of GMR-lacZ. The fragment did not include the
transcription start site. The activity levels and sex ratio from arm*-
GMR-lacZ were similar to those in flies without the arm fragment
(Table 1). We next tested an oligonucleotide containing four
consecutive GAGA sites and three DRE sites, designed to mimic
sequences known to bind GAGA factor and DREF in vitro [48,49].
The activity of DRE/GAGA-GMR-lacZ was lower in both sexes than
GMR-lacZ alone, suggesting that the DRE and/or GAGA elements
have inhibited GMR-mediated transcription enhancement. How-
ever, the male hyper-activity was significantly higher than for GMR-
lacZ (P,0.05, T-test).
We expanded on these observations with DRE/GAGA-GMR-
lacZ. We targeted the construct to the attP landing sites and 6E and
20C, and found similar responses of the transgene at all locations.
We checked that the observed increase was specific to the X
chromosome, by targeting the construct to an autosomal attP (at
86F). Indeed, males and females with DRE/GAGA-GMR-lacZ at
86F had similar activity levels (Table 1). We crossed the DRE/
GAGA-GMR-lacZ 2A line to an hsp83-msl2/Sb line, and found that
female offspring with hsp83-msl2 had a significantly higher beta-
galactosidase activity (P,0.05, T-test) than those without (Table 2);
a response to induced MSL complex equal in magnitude to that of
arm-lacZ. This argues that the male-specific increases observed
above were likely due to the MSL complex.
Figure 2. Transgenic lacZ constructs used in this study. A–H) The
lacZ ORF is the solid black box, surrounded by 59 and 39 regulatory
sequences. Transcription start points represented with bent arrows.
Unlabelled elements are identical to the construct immediately above.
A, F, G) Sequences identical to, or one mis-match from, the DRE
consensus sequence WATCGATW [82], and GAGA (or TCTC), are
indicated with points and + symbols, respectively. F) The fragment
from the armadillo promoter included in arm*-GMR-lacZ is underlined in
panel A.
doi:10.1371/journal.pone.0020455.g002
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does not respond to the MSL complex because of the hsp70
minimal promoter. To separate the GMR elements from the hsp70
sequences, we replaced the hsp70 TATA with a basal promoter
(242 to +23) from the X-linked dosage compensated Pgd gene
[50]. The activity from GMR-pgd-lacZ was much reduced
compared to GMR-lacZ in both sexes (Table 1), which was not
unexpected given that the hsp70 promoter has a relatively high
basal activity at 25uC [51]. However, male hyper-activity was
significantly higher than for GMR-lacZ (P,0.05, T-test) and
dosage compensation appeared to be partially restored.
Hyper-activity of GMR-lacZ in homozygous females
The two methods for comparing male and female activity of all
GMR-based constructs appeared to give slightly different results.
Constructs with very low hyper-transcription (e.g. GMR-lacZ,
arm*-GMR-lacZ) had no dosage compensation, and those with
high male hyper-transcription (GMR-pgd-lacZ, DRE/GAGA-GMR-
lacZ) had only modest dosage compensation. Because (hemizy-
gous) males in each measurement were genetically identical, this
anomaly can only be explained by differences in female
expression. Due to experimental variation, the raw male or
female activities cannot be directly compared without first
controlling for variation by normalization, as with a male to
female ratio. But if we instead calculate the inverse (female to
male) ratios, then we have comparable activity estimates of
females, normalized to single-copy males (Table 3). As expected,
females carrying two copies of arm-lacZ had about twice the
activity of single-copy females, which is why a male hyper-activity
of two-fold (log2 of 1.0) is sufficient to dosage compensate. But
females with two copies of all GMR-based constructs have more
than twice the activity of single-copy females. This explains the
discrepancy: a slight male hyper-activity was only sufficient to
equal about half the activity of paired females, and full
compensation would require male hyper-activity of around 2.5
to 3.0-fold (log2 of 1.3–1.6). The significance of this homozygous
effect is discussed below.
Early or constitutive expression of GMR-lacZ is insufficient
to lead to compensation
It was also possible that GMR-lacZ failed to compensate because
of problems with expression time or specificity. Perhaps dosage
compensation was less efficient in the developing eye tissue. The
set of MSL-bound genes in larval salivary glands appears to be a
subset of the total MSL-bound genes in early embryos, prompting
the suggestion that MSL complex may bind early, and maintain
largely stable binding through development [18]. The same
conclusion was reached after observing that MSL complex can
colocalize with RNA polymerase II on salivary gland chromo-
somes, but remain bound after polymerase dis-associates [52]. We
next tested the relative importance of early and constitutive
expression on the late, tissue-specific compensation of GMR-lacZ.
We placed the tetO tetracycline operator upstream of GMR-lacZ
to allow additional regulation through the tetracycline system [53].
DNA binding of the tetracycline-controlled transcriptional activa-
tor (tTA) is inhibited if tetracycline is added to the culture media
(i.e. a tet-OFF system). Early expression of tTA was driven by
promoters from the nullo and serendipity alpha genes [54]. nullo and
serendipity alpha encode proteins that are required for cellularization
and are predominately expressed in the early stages of embryo-
genesis [55]. Expression from each activator (n1-tTA and s1-tTA,
respectively) is sufficient to lead to cell death through expression of
Table 1. beta-galactosidase activity of lines carrying lacZ constructs at differing attP sites.
Heterozygous (1 dose) Homozygous (2 doses)
attP Activity
1 Male/Female Activity Male/Female
Construct Location Male Female Ratio log2(Ratio) Male
2 Female Ratio log2(Ratio)
arm-lacZ X 2A 0.3560.03
3 0.2060.03 1.8460.14 0.8760.11 0.3160.02 0.3260.01 0.9560.04 20.0760.06
6E
4 0.5060.04 0.3560.02 1.4660.08 0.5460.08 0.4360.02 0.5060.02 0.8560.02 20.2360.04
20C
4 0.4760.05 0.2660.03 1.8660.07 0.8960.06 0.4260.01 0.4460.02 0.9560.07 20.0960.11
GMR-lacZ 3 86F 2.4660.13 2.0560.03 1.2060.06 0.2660.07 6.2860.36 4.8960.05 1.2860.08 0.3660.09
X 2A 2.3560.07 1.8560.04 1.2860.06 0.3560.07 1.2860.05 2.5260.11 0.5160.02 20.9760.05
6E 1.8160.11 1.6060.14 1.1360.04 0.1860.05 0.9560.02 1.7960.08 0.5360.01 20.9260.04
20C 2.1160.02 1.7260.04 1.2360.03 0.3060.03 1.1360.06 2.1460.11 0.5360.03 20.9260.07
GMR-pgd-lacZ X 2A 0.08960.002 0.05060.002 1.7960.11 0.8360.09 0.13060.005 0.20460.011 0.6460.05 20.6560.13
GMR-lacZ-SV40 X 2A 4.0760.07 2.9360.07 1.3960.04 0.4760.04 5.7260.28 9.3260.38 0.6160.02 20.7160.05
GMR-lacZ-SV40-
18D
X 2A 5.3860.12 3.8860.09 1.3960.03 0.4760.03 4.5960.37 9.3160.54 0.4960.02 21.0260.05
arm*-GMR-lacZ X 2A 2.0860.02 1.6860.01 1.2460.01 0.3160.02 2.0260.11 4.2960.23 0.4760.02 21.0860.07
DRE/GAGA-GMR-
lacZ
3 86F 0.2960.01 0.2860.01 1.0560.01 0.0760.02 0.9060.03 1.0060.03 0.9160.05 20.1460.08
X 2A 0.35360.005 0.21560.002 1.6460.01 0.7160.01 0.29360.011 0.54560.031 0.5460.03 20.8960.08
6E 0.4660.02 0.3360.01 1.3860.05 0.4660.06 0.7360.01 1.3960.05 0.5260.02 20.9360.06
20C 0.07460.002 0.04360.001 1.7160.01 0.7760.01 0.09060.010 0.13660.016 0.6660.01 20.6060.03
1OD/min/mg protein.
2X-linked males hemizygous; only one dose of transgenic cassette.
3All data are means of triplicates 6 standard error.
4Measured in hemisected adults; all others, adult heads.
doi:10.1371/journal.pone.0020455.t001
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ala5 transgene, but only in the absence of tetracycline [54].
arm-tTA [56] was used as a constitutive driver of tTA.
We crossed flies carrying tetO-GMR-lacZ to lines with arm-tTA, n1-
tTA,o rs1-tTA activators, and raised the offspring in the absence of
tetracycline. We measured the male hyper-activity of beta-
galactosidase in adult heads (Table 4), and compared the responses
to those of arm-lacZ and GMR-lacZ (Figure 4A). Males and (single-
copy) females of all crosses had very similar activities. The response
to additional constitutive expression provided by arm-tTA was
evident in the very high activities in offspring of this cross. Further,
Table 2. Effect of hsp83-msl2 on female beta-galactosidase
activity.
Activity
1 Sb
+/Sb
2
Construct
lacZ/+; hsp83-
msl2 lacZ/+;S b Ratio log2(Ratio)
arm-lacZ 0.27760.0213 0.21960.005 1.2760.10 0.3360.11
GMR-lacZ 2.5260.14 2.6960.08 0.9460.04 20.1060.07
DRE/GAGA-GMR-
lacZ
0.6560.03 0.5160.03 1.2960.01 0.3760.01
1OD/min/mg protein.
2w; +/CyO; P{w
+=hsp83-msl2}/ TM6C, cu
1 Sb
1 males were crossed to females
carrying the appropriate lacZ cassette at 2A, and Sb and Sb
+ daughters
compared.
3All data are means of triplicates 6 standard error.
doi:10.1371/journal.pone.0020455.t002
Table 3. Increase in female head beta-galactosidase activity
when homozygous for the lacZ transgene.
Female Activity
1 Homozygous
Construct Location One Dose Two Doses Increase
arm-lacZ 2A 0.5560.04 1.0560.04 1.91
6E
2 0.6960.04 1.1760.03 1.70
20C
2 0.5460.02 1.0760.08 1.98
GMR-lacZ 2A 0.7960.04 1.9760.06 2.49
6E 0.8860.03 1.8960.05 2.15
20C 0.8160.02 1.9060.09 2.35
GMR-pgd-lacZ 2A 0.5460.05 1.5860.15 2.82
GMR-lacZ-SV40 2A 0.7260.02 1.6360.06 2.26
GMR-lacZ-SV40-18D 2A 0.7260.01 2.0460.08 2.83
arm*-GMR-lacZ 2A 0.8160.01 2.1360.11 2.63
DRE/GAGA-GMR-lacZ 2A 0.6160.01 1.8660.11 3.05
6E 0.7360.03 1.9160.07 2.62
20C 0.58660.005 1.51460.031 2.56
1Mean OD/min/mg protein, normalized to single dose male activity, 6 standard
error, n=3.
2Measured in hemisected adults; all others, adult heads.
doi:10.1371/journal.pone.0020455.t003
Figure 3. The promoter affected compensation of lacZ-mediated beta-galactosidase activity. beta-galactosidase activity was measured in
transgenic males and females carrying the indicated lacZ constructs at defined attP landing sites (2A, 6E, 20C) on the X chromosome. Top panels:
Hemizygous male activity was compared to heterozygous female activity to measure level of male hyperactivation (A 2-fold increase = log2 of 1).
Bottom panels: Hemizygous male activity was compared to homozygous female activity to measure efficiency of dosage compensation (complete
compensation = log2 of 0). Means of triplicates were plotted, with 1 standard error.
doi:10.1371/journal.pone.0020455.g003
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no response when flies were raised with tetracycline (mean male
activity of 2.1560.06, female of 1.6460.07 OD/min/mg). A
separate cross to ywflies (parental strain), which lack tTA, showed
that the tetO sequences alone had little effect on activity from GMR-
lacZ (Table 4). To confirm that the tTA drivers were active in the
early embryo, we crossed the tTA driver lines to a tetO-YFP
responder line [57] and examined the offspring for yellow
fluorescence (Figure 4B). We found that all tTA drivers were
effective at inducing YFP expression well above background levels.
To confirm that regulation via the tetracycline system was
capable of shifting the expression pattern of tetO-GMR-lacZ,w e
crossed the reporter line to arm-tTA flies and observed the altered
expression pattern in climbing third instar larvae (Figure 5). The
GMR enhancer/promoter is active in all cells in, and posterior to,
the morphogenetic furrow in the developing eye-antennal disc in
third instar larvae [6]. In a control cross to ywflies, beta-
galactosidase staining could be detected in the developing eye,
posterior to the morphogenetic furrow, and to a limited extent in
the brain, consistent with Glass expression [30]. When crossed to
arm-tTA, beta-galactosidase could also be detected in the brain and
most other larval tissues (Figure 5). This response was specific to
arm-tTA as it was inhibited with the addition of tetracycline to the
culture medium. Given that the tetO-GMR-lacZ reporter could
respond to additional regulation through the tetracycline system,
and that the activators were all active in the early embryo, we
concluded that the above test of effect on dosage compensation
was valid. Therefore, additional early or constitutive expression of
GMR-lacZ was insufficient to affect dosage compensation. The
time and specificity of expression may have been relatively less
important than the nature of the promoter/enhancer.
However, the staining for beta-galactosidase (Figure 5) revealed
a surprising observation. The pattern of staining seen with arm-tTA
activation of tetO-GMR-lacZ did not equal the pattern from the
arm-lacZ positive control line. The tetO-GMR-lacZ reporter was
widely expressed with the notable exception of the developing
imaginal discs, beyond the Glass-expressing areas of the eye-
antennal disc. As the fragment of armadillo was the same in arm-tTA
and arm-lacZ [56], it appears that tetO-GMR-lacZ was being
repressed in these tissues. These results suggest that the 29 bp
GMR enhancer contains the binding site for a repressor that is
being expressed in imaginal cells.
Discussion
Our attempt to screen for modifiers of dosage compensation
was thwarted by the failure of GMR-hid to be well compensated.
The transgene did not acquire compensation in an X chromosome
environment, nor when coupled to strong MSL attractors.
Quantitative measurements with the lacZ gene confirmed that
the GMR-hsp70 enhancer-promoter was at fault. We believe that
this is not due to lack of local MSL complex, but rather an inability
of the complex to regulate GMR-mediated transcription.
This was most evident in the phenotype of the GMR-hid lines
with the 9-copy multimer of the roX1 DHS. In most of these lines,
Figure 4. Compensation of tetO-GMR-lacZ was unaffected by
additional early or constitutive expression. A) Equality of beta-
galactosidase activity between the sexes was measured in adult heads
of flies carrying one copy of tetO-GMR-lacZ (at the 2A attP site), and one
copy of the indicated tetracycline driver. ywflies have no tTA driver.
The responses of arm-lacZ and GMR-lacZ at 2A are provided for
comparison. Flies were raised in the absence of tetracycline to promote
transcription activation by tTA. Means of triplicates were plotted, with 1
standard error. B) Activity of the tTA drivers was detected as yellow
fluorescence (through a green filter set) in embryos carrying one copy
of tetO-YFP, and one copy of the indicated drivers, raised without
tetracycline. White light (top of each pair), and fluorescent images of
the embryos at different time points after egg laying were recorded.
Dorsal up, anterior left. The solid line bisecting each embryo is the edge
of tape used to mount the embryos.
doi:10.1371/journal.pone.0020455.g004
Table 4. Effect of tTA drivers on beta-galactosidase activity
from tetO-GMR-lacZ.
Cross Activity
1 Male/Female
lacZ x Driver Male Female Ratio log2(Ratio)
tetO-GMR-lacZ x( yw ) 1.5360.05
2 1.4060.08 1.1060.03 0.1360.04
x s1-tTA 1.7060.04 1.9160.06 0.8960.04 20.1760.07
x n1-tTA 1.7460.03 1.6260.03 1.0760.03 0.1060.04
x arm-tTA 8.7060.53 7.3560.20 1.1960.10 0.2460.13
1OD/min/mg protein.
2All data are means of triplicates 6 standard error.
doi:10.1371/journal.pone.0020455.t004
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variegation in pigmentation patterns in several lines, suggesting
repression of the mini-white marker gene. It had been previously
shown that recruitment of the MSL complex to a roX1 transgene
led to relief of repression of mini-white [41]. Similarly, MSL
complex recruited to the roX1 DHS in the (roX1 DHS)9-GMR-hid
lines may have been sufficient to relieve repression on mini-white.
However, there was little difference in eye size, suggesting that
GMR-hid was not responding to the bound MSL complex. Lack of
response to MSL complex is also consistent with our observations
that strong MSL binding sites had no effect on GMR-lacZ beta-
galactosidase activity. While formally possible that local MSL
complex was limiting at each site, the large number of lines
screened makes this unlikely. Certainly local MSL complex at the
2A, 6E, and 20C attP sites was sufficient to up-regulate arm-lacZ,
yet had no effect on GMR-lacZ. The most likely explanation is that
expression from the GMR-hsp70 enhancer-promoter was not
responsive to MSL complex.
Our observation that the promoter can affect dosage compen-
sation was somewhat surprising. The MSL complex binds the
male X chromosome most strongly at 150 to 300 mostly non-
coding GA-rich MRE sequences [38,39] but is also highly
enriched across most active X-linked genes, with a bias towards
the 39 end [17,18,19]. It has been proposed that the complex
initially binds to the MRE sites and then spreads to active genes
[38]. In support of this model, the MSL complex is attracted to
ectopically-transcribed portions of the X chromosome, created
when random insertions of a UAS-hsp70 TATA transgenic
promoter are induced with GAL4 [58]. Further, the complex is
recruited to transgenic autosomal insertions of the X-linked mof
gene, but only when mof is transcribed [59]. As recruitment still
occurs when mof is transcribed from a tubulin promoter, GAL4
UAS sequences, or even in an antisense direction, Kind and
Akhtar conclude that ‘‘the type of promoter and direction of
transcription are not [important]’’. It appears that some feature of
transcription itself, or an active chromatin state, may be
responsible for recruitment of MSL complex to the many genes
on the X chromosome. This may involve the chromo domain of
MSL3, which recognizes histone H4 monomethylated at lysine 20
[60,61], a marker for active genes in human cells [62].
Accordingly, autosomal genes transposed to the X chromosome
acquire MSL binding, H4K16 acetylation, and dosage compen-
sation, but only when the transposed genes are transcribed [63].
However, transcription was disabled by deleting promoter regions.
Figure 5. tetO-GMR-lacZ responded to tTA in brain and other tissues but not imaginal discs. Third instar larvae of the indicated strains,
raised with (+) or without (2) tetracycline (tet) in the diet, were dissected and stained with X-gal for lacZ expression. Additional induction of tetO-
GMR-lacZ occurs with arm-tTA in the absence of tetracycline. ywand arm-lacZ provided as negative and positive controls for lacZ expression,
respectively. All staining and photographic conditions were equal across all sets. Bar =0.2 mm.
doi:10.1371/journal.pone.0020455.g005
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the same X-linked sites where arm-lacZ did, argues that
transcription alone is not sufficient for a gene to be compensated,
and that the importance of a gene’s promoter in dosage
compensation cannot be ignored. Indeed, studies of the X-linked
white gene concluded that the gene contains multiple elements that
influence dosage compensation, some near the promoter and some
in the coding region [64,65]. Further, it has been suggested that
DNA supercoiling factor bound at promoter regions may facilitate
loading of the MSL complex onto active genes [33]. DNA
supercoiling factor contributes to Drosophila dosage compensation
[10].
Our efforts to determine why genes driven by the GMR
enhancer-promoter do not respond to the MSL complex were
complicated by the surprising observation that activity in
homozygous females was more than twice that of hemizygous
females. We believe this may be because of a complex interplay
between the Glass transcription factor and an unknown repressor.
As a consequence of the hyperactivity in homozygous females, the
comparison of the activity of one dose males with one dose females
provides a more accurate view of male hyperactivation. Of the
various gene constructs evaluated, two showed a significant
increase in activity in males. In one construct, the hsp70 basal
promoter was replaced with the weaker basal promoter from the
X-linked dosage compensated Pgd gene. This suggests that the Pgd
basal promoter contains elements that are important for
recruitment of the MSL complex to the reporter gene and that
the hsp70 basal promoter lacks these elements. The white gene
promoter was concluded to be important for dosage compensation
because autosomal white transgenes driven by the full heat-
inducible hsp70 promoter were expressed equally in males and
females [64]. Autosomal white transgenes are typically expressed at
higher levels in males than females [66]. An alternative
interpretation of these results is that the hsp70-white transgene is
not compensated because the hsp70 promoter does not respond to
the MSL complex. The Pgd promoter did not contain any obvious
binding sites for known transcription factors. Widely expressed
genes such as Pgd and arm generally contain similar levels of RNA
polymerase II at 59 and 39 regions of the transcription units [67]. It
has been suggested that RNA polymerase II stalling at 59 ends
depends upon core promoter elements that are absent in
constitutively expressed genes [67]. Thus it may be of interest to
determine if the MSL complex can only regulate those X-linked
genes that do not have stalled promoters. The other construct that
showed significant increased activity in males contained binding
sites for the GAGA and DREF DNA binding proteins upstream of
the GMR-hsp70 enhancer-promoter. The DREF and/or GAGA
factors could create a local chromatin environment that facilitates
recruitment of the MSL complex or could interact directly with
the complex. It may now be beneficial to separate the effects of
DRE and GAGA elements, and determine such characteristics as
motif strength, placement, and repeat spacing. Such studies may
explain why addition of a fragment from the arm promoter that
contained predicted GAGA and DREF sites, did not lead to a
significant increase in GMR-lacZ expression in males. We found no
support for the notion that late or tissue-specific expression was a
factor in poor compensation, although it is possible that these
factors affect compensation of other genes. Thus we conclude that
genes driven by the GMR-hsp70 enhancer-promoter do not
respond to the MSL complex because of the nature of the hsp70
basal promoter and because it lacks elements such as GAGA and
DREF binding sites.
A curious possibility is that any one of the promoter
modifications could have caused or increased repression of the
transgene, perhaps via the putative repressor detected in larval
staining for beta-galactosidase. This may be reflected in the
generally lower beta-galactosidase activity in lines with pgd-GMR-
lacZ and DRE/GAGA-GMR-lacZ transgenes. Knowing that MSL
complex can act to relieve repression in males, such changes would
also register in our tests as an apparent increase in male hyper-
activity. However, we cannot distinguish between general
repression with male-specific relief, and more simple male
enhancement, as our assays were designed to measure the final
result of dosage compensation.
Can our results shed any insight into why other X-linked genes
are not dosage compensated? The non-compensated X-linked
Lsp1alpha gene has been particularly well studied [42,68,69].
Lsp1alpha is not enriched for H4K16ac in the tissue in which it is
active [42]. Similarly, the runt gene, which is dosage compensated
by an MSL-independent mechanism [70], is not enriched for
H4K16ac in Drosophila embryos [16]. Thus it appears that these
genes are not hypertranscribed by the MSL complex due to a
failure to recruit the complex rather than because their promoters
lack certain elements. Indeed, X-linked lacZ transgenes driven by
the Pgd promoter are enriched for H4K16ac [42]. Whether or not
this is the general explanation for why some X-linked genes are
not compensated would require a more global approach to
compile a list of non-compensated genes. To our knowledge no
such list exists, however it may be possible to do this using the
extensive existing data sets of male vs female expression, MSL2
RNAi knockdown in cell lines and MSL complex binding and
H4K16ac enrichment profiles [13,38,71,72]. However, in general
almost all active genes on the male X chromosome are enriched
for H4K16ac, which has a broader distribution profile than the
MSL complex [13]. Thus since there are very few active X-linked
genes that are devoid of H4K16ac, either there are very few non-
compensated genes or other factors such as the nature of the gene
promoter influence male hypertranscription.
Beyond the promoter, our experiments also revealed that
another factor can affect the degree of compensation. Two copies
of all GMR cassettes had more than twice the beta-galactosidase
activity of one copy, instead increasing three- to four-fold. As we
only measured this effect in females with X-chromosomal
insertions, it would be interesting to extend the experiments to
autosomes and males. The non-linear effect did not occur with
arm-lacZ, and is not a property of the beta-galactosidase assay,
which is linear across a 100-fold range of protein extract
concentration [51]. As a similar effect occurred in all cassettes
with GMR, regardless of the surrounding sequences, the effect
appears to be due to paired GMR enhancer elements. Homolo-
gous chromosomes in Diptera pair through all mitotic stages, not
just during meiosis [73]. Paired homologues can share transcrip-
tion factors or chromatin regulators, which can affect transcription
in a variety of ways known as ‘transvection’ [74]. The pairing
effect of GMR may similarly reflect synergy in the binding or
activity of positive factors such as Glass. Conversely, negative
regulators such as the putative repressor could have less effect on
the paired GMR elements than would be expected for two un-
paired elements. We attempted to determine if the non-linear
response was pairing-dependent by measuring two copies of GMR-
lacZ cassettes at different locations, but found that the differing
activity levels at each location precluded conclusions based on
mixed genotypes. Whatever the cause, the non-linear effect has
consequences for dosage compensation of GMR-lacZ, as male
expression needs to be more than doubled to equal the paired
female levels.
More generally, a description of X chromosome dosage
compensation as a transcriptional doubling by the MSL complex
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chromosomal transcripts reduced a variable amount after knock-
down of msl-2, with median decreases of about 1.3 to 1.7-fold
[72,75]. Recent estimates based on high-throughput sequencing of
RNAs in S2 cells put the effect of MSL-mediated up-regulation at
about 1.4-fold [71]. Zhang et al. believe that the remaining up-
regulation required to equalize gene dose is likely provided by a
separate mechanism that also compensates for aneuploid regions
genome-wide. Gene expression in aneuploid regions of S2 cells, or
in chromosome aberrations, can be ‘‘buffered’’ to varying extents,
with levels closer to wild-type than would be expected from gene
copy number [71,76,77]. If Drosophila males have indeed evolved
to co-opt gene buffering as a part solution to X chromosomal
haploidy, then dosage compensation should be viewed as a
combinatorial process. At the level of an individual X-linked gene,
male expression may be affected by any or all of several
mechanisms, including aneuploidy-type buffering, dose-dependent
regulatory feedback, and MSL-mediated up-regulation. Given that
the paired female X-linked genes might also be affected by
transvection, dosage compensation could be seen as merely the
result of a combination of mechanisms. Care must be taken in the
design of experiments to ensure the correct biological process is
measured.
Finally, it should be noted that the tissue-specificity of the GMR
enhancer appears to reflect more than simple activation by the
Glass transcription factor. We observed a general lack of GMR-
lacZ expression in larval imaginal tissues beyond those that express
Glass. This repression pattern is similar to that observed for
another Glass reporter, ‘‘38-1’’, a pentamer of a larger (38 bp)
fragment from the Rh1 proximal enhancer spanning the Glass
binding site [30]. 38-1 cannot respond to glass overexpression
(from a hsp70-glass transgene) in imaginal tissue with the exception
of a small number of cells in the leg disc. In contrast, in response to
glass overexpression, 38-1 directs lacZ expression in many cells in
the brain and central nerve cord. A shorter 29 bp enhancer
(GMR) responded more strongly to glass overexpression, directing
lacZ expression in many cells in the brain and in all cells of the
eye/antennal and leg discs. It was concluded that shortening the
enhancer to 29 bp had deleted the binding site for a putative
repressor that inhibits Glass activity in non-photoreceptor cells
[30]. DNA sequencing of GMR-lacZ used in this study confirmed
that we were using the pentamer of the 29 bp element. One
explanation for our results is that the repressor binding site was not
completely removed when shortening the fragment from 38 to
29 bp, merely weakened to allow dominance of high levels of Glass
over the repressor. Alternatively, the 38 bp enhancer contains
binding sites for two repressors, one of which is retained in the
29 bp GMR enhancer. Additional studies would be required to
distinguish between these two possibilities. In either case, it
appears that the tissue-specific expression directed by the 29 bp
GMR enhancer is due to combined action of the Glass activator
and an unknown repressor.
Materials and Methods
Recombinant DNA
Standard molecular cloning techniques [78] were used, with
clones confirmed by restriction analysis, PCR, or DNA sequencing.
hid gene constructs. An EcoRI to EcoRI fragment of pBS
SK hid cDNA [7], encoding hid cDNA, was inserted into the
EcoRI site of pGMR-1 [4] to create pGMRhid, which contains
the GMR-hid cassette used for most GMR-hid lines. A XhoI to NotI
fragment of pCaSpeR3 roX1 DHS short or pCaSpeR3 roX1 DHS
short multimer [26], containing the roX1 DHS or its multimer, was
inserted into the XhoI site of pGMR-1, with the aid of
oligonucleotides (59-TCGACGTTTAAACGGTTGGCC-39 and
59-AATTGGCCAACCGTTTAAACG-39) annealed to link
EcoRI and XhoI sites, to create pCL02 or pCL03, respectively.
A EcoRI to EcoRI fragment of pBS SK hid cDNA containing hid
was inserted into the EcoRI site of pCL02 or pCL03, to create
pRGH and pR9GH, which contained the roX1 DHS-GMR-hid or
(roX1 DHS)9-GMR-hid cassettes, respectively. pCaSpeR3 18D10-L
monomer or pCaSpeR3 18D10-L4mer [40] was digested with
NotI, treated with Klenow fragment, then digested with BamHI,
and the fragment encoding the 18D site, or its multimer, was
inserted into the BglII and StuI sites of pGMRhid to created
p18DGH, and p18D4GH, which contain the GMR-hid-18D and
GMR-hid-(18D)4 cassettes, respectively. An EcoRI to EcoRI
fragment of pTAattB [43], encoding attB, was treated with
Klenow fragment and inserted into the EcoRV and SmaI sites of
pBluescript II KS+ (Invitrogen) to create pBSattB. pBSattB was
partially digested with XhoI and re-ligated to remove the XhoI
site, then a HindIII to HindIII fragment of pGMR-1, encoding
mini-white and GMR, was inserted into the HindIII site to create
pBSw+GMRattB. An EcoRI to EcoRI fragment of pBS SK hid
cDNA, encoding hid cDNA, was inserted into the EcoRI site of
pBSw+GMRattB to create pGHattB, which contains the GMR-hid
cassette used for phiC31-mediated transformations (lines C70,
C72, C74).
lacZ constructs. An EcoRI to EcoRI fragment of pTAattB,
encoding attB, was inserted into the EcoRI site of pCaSpeR-arm-
betagal [79], to create pALattB, which contains the arm-lacZ
cassette. pCaSpeR-arm-betagal was digested with XbaI, treated
with Klenow fragment, and digested with SmaI, then the fragment
encoding lacZ was inserted into pBC KS + (Invitrogen) to create
pBClacZ. A BamHI to EcoRI fragment of pBClacZ, encoding
lacZ, was inserted into the BglII and StuI sites of pBSw+GMRattB
to create pGLattB, which contains the GMR-lacZ cassette. To
make pGMR-pgd-lacZ, pGLattB was digested with XbaI (partial)
and EcoRI and the excised hsp70 minimal promoter was replaced
with a 70 bp linker that contained the Pgd minimal promoter. The
70 bp linker was made by annealing the oligonucleotides 59-
CTAGAACAGTGCCATATATAGATTGTAACATTAGGAG-
CTCAAATCATTGTTGGAACACAAACCACAAAG-39 and 59-
AATTCTTTGTGGTTTGTGTTCCAACAATGATTTGAGC-
TCCTAATGTTACAATCTATATATGGCACTGTT-39. pGL-
H was made by digestion of pGLattB with HindIII (partial) and re-
ligation to remove the site in the pUC backbone. A SmaI to
HindIII fragment of pCaSpeR-arm-betagal, encoding lacZ and
SV40 39 UTR, was inserted into the EcoRI (filled) and HindIII
sites of pGL-H to create pGLSV40attB, which contains the GMR-
lacZ-SV40 cassette. A SmaI to HindIII fragment of pBS2-
N17merHF12-1x12 [80] encoding lacZ, SV40 39 UTR and the
18D site, was inserted in the (blunted) EcoRI and (remaining)
HindIII sites of pGL-H to create pGLSV4018DattB, which
contains the GMR-lacZ-SV40-18D cassette. A XhoI to XhoI
fragment of a PCR amplicon (primers 59-CCGGAATTCT-
CGAGTGGAATGTAAACAATGCCACAGAC-39 and 59-CC-
GGAATTCTCGAGTAAACGGAACAGAATCACAGATGC-39)
of the armadillo promoter, from pCaSpeR-arm-betagal was inserted
in the XhoI site of pGLattB to create pCL12, which contains the
arm*-GMR-lacZ cassette. Four oligonucleotides (59-AATTGCTC-
GAGCTAGCTATCGATAGATTCCCTGCTATCGATAGA-
TTCCCTGCTATCGA-39,5 9-TAGATTCGCTAGCAGATC-
TCTCTCGTTCATTGAGAGAGCAAAGGCCTCTCTCGTT-
CATTGAGAGAGATCTCGAG-39,5 9-AATTCTCGAGATCT-
CTCTCAATGAACGAGAGAGGCCTTTGCTCTCTCAATG-
AACGAGA-39, and 59-GAGATCTGCTAGCGAATCTATCG-
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ATAGCTAGCTCGAGC-39) were annealed to create 3 DRE
and 4 GAGA sites, digested with XhoI, and inserted into the XhoI
site of pGLattB to create pCL13, which contains the DRE/GAGA-
GMR-lacZ cassette. A XhoI-SacI fragment of pW.T.P-2 [53],
encoding tetO, was inserted with the aid of oligonucleotides (59-
CTTTAAACGGTTGGCG-39 and 59-TCGACGCCAACCGT-
TTAAAGAGCT-39), annealed to link SacI to XhoI, in the XhoI
site of pGLattB to create pCL21, which contains the tetO-GMR-
lacZ cassette. The linkers are 39 of the tetO.
Drosophila genetics, transformation, image capture and
beta-galactosidase assays
To observe GMR-hid eye size with msl deficiencies, msl2 msl1
mle/CyO males were mated to virgin GMR-hid C60 females, and
Cy and Cy
+ offspring compared. To observe GMR-hid eye size
with constitutive expression of msl2, virgin GMR-hid C60 females
were separately crossed to w; msl1
L60/CyO; P{w
+ = hsp83-msl2}
males [36] and y
1 w
1; msl1
L60/CyO, pr cn
2 y
+ males. Curly offspring
of each cross were compared. To measure GMR-lacZ activity with
constitutive expression of msl2, w; msl1
L60/CyO; P{w
+=hsp83-
msl2} males were crossed to virgin w
1118; P{w
+mC = hs.hid}3, Dr
1/
TM6C, cu
1 Sb
1 females, then the resulting curly-winged, stubble-
bristled males were mated to virgin females carrying the
appropriate lacZ cassette at 2A, and Sb and Sb
+ daughters
compared.
Right-hand-side adult eyes that best represented the modal
average eye size of each line were illuminated with reflected
halogen light. Images of the lines carrying (roX1 DHS)9-GMR-hid
were captured with a Magnafire camera and software (Optronics),
and the RGB colour balance manually altered to best match other
images. All other images were captured with an Olympus DP-70
camera, with the provided software or with Soft Imaging System
analySIS FiVE 5.0, and balanced RGB on white card to control
for exact lighting conditions. The exposure time was automatically
determined by the software.
P-element mediated transformation of Drosophila was performed
as previously described [24]. phiC31 recombinase mediated
transformation was performed using strains that contained both
an attP landing site and expressed recombinase in the germ-line
[44]. Transgenic flies were back-crossed to the ywline, established
as homozygous or balanced lines, and confirmed by PCR both
within the insert and across the insert/landing site boundary.
Beta-galactosidase assays of hemisected adults or heads were
conducted based on the procedure of Simon and Lis [51]. If
necessary, tetracycline was added at 10 ug/mL to the media, and
flies raised in the dark. New emerged flies were collected and then
aged 3 to 5 days at before the assay. For each replicate, 9 females
or 12 males were hemisected to remove wings, legs, and
abdomens, or 15 female and 20 male heads used. The mean
activities of males, females, or ratios between the sexes, are
displayed with standard errors (one standard deviation / square
root of sample size (3)), with a log2 transformation then often
applied to allow better comparisons of different ratios. Two
sample, two-tailed Student’s t-tests were conducted in the R
software environment, using (the default) Satterthwaite’s approx-
imation. Tissue dissected from climbing third instar larvae was
stained with X-gal essentially as described by Glaser et al. [81].
The stained tissue was mounted in 90% glycerol, and photo-
graphed under transmitted white light at 1/90 second exposure,
ISO 200, with an Olympus DP-70 camera.
Supporting Information
Figure S1 GMR-hid did not respond to the MSL
complex. Eyes of flies that carried a single copy of the GMR-
hid transgene (line C60), and were either wild type for the msl
genes, heterozygous for msl1, msl2 and mle or constitutively
expressed msl2 (hsp83-msl2). If GMR-hid on the X chromosome
responded to levels of the MSL complex then the eye size in msl1
msl2 mle heterozygous males should have been larger than control.
Similarly, eyes of females that expressed msl2 should have been
smaller than control.
(TIF)
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